Morgan Stanley Sigilon Therapeutics, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.34 - $1.38 $73,672 - $299,025	216,685 Added 718.83%	246,829 $229,000
Q4 2022 Feb 14, 2023	BUY	$0.29 - $0.69 $229 - $545	790 Added 2.69%	30,144 $10,000
Q3 2022 Nov 14, 2022	SELL	$0.48 - $0.86 $6,044 - $10,829	-12,592 Reduced 30.02%	29,354 $15,000
Q2 2022 Oct 27, 2022	SELL	$0.74 - $1.64 $10,373 - $22,989	-14,018 Reduced 25.05%	41,946 $35,000
Q2 2022 Aug 15, 2022	SELL	$0.74 - $1.64 $10,373 - $22,989	-14,018 Reduced 25.05%	41,946 $35,000
Q1 2022 Oct 27, 2022	BUY	$1.24 - $3.03 $17,382 - $42,474	14,018 Added 33.42%	55,964 $82,000
Q1 2022 May 13, 2022	SELL	$1.24 - $3.03 $421,640 - $1.03 Million	-340,033 Reduced 85.87%	55,964 $82,000
Q4 2021 Feb 14, 2022	SELL	$2.58 - $6.13 $284,625 - $676,261	-110,320 Reduced 21.79%	395,997 $1.09 Million
Q3 2021 Nov 15, 2021	BUY	$4.42 - $10.61 $2.24 Million - $5.37 Million	506,317 New	506,317 $2.86 Million

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.